Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US75886F1075
Ticker REGN
Company REGENERON PHARMACEUTICALS
Currency $
Price
Aware Investor Index (AII) 0.0031
Recommendation STRONG SELL
P/E 127.02
ROE 6.11 %
Capitalization 47,702,316,060 $
Dividend Yield 0.00 %
P/S 8.12
AII Position 661
P/E Position 713
ROE Position 569
Capitalization Position 182
Dividend Yield Position 596
Sales 5,872,227,000 $
10-Year Average Earnings 375,545,400 $
Shares Outstanding 115,954,000
Equity 6,144,078,000 $
Dividend per Share 0 $
Industry Pharmaceutical
Country United States
REGENERON PHARMACEUTICALS Investor Relations Web Site http://investor.regeneron.com/







Sales:

YEAR MONTH AMOUNT
2017 12 5,872,227,000.00 $
2016 12 4,860,427,000.00 $
2015 12 4,103,728,000.00 $
2014 12 2,819,557,000.00 $
2013 12 2,104,745,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 1,198,511,000.00 $
2016 12 895,522,000.00 $
2015 12 636,056,000.00 $
2014 12 338,126,000.00 $
2013 12 413,738,000.00 $
2012 12 750,269,000.00 $
2011 12 -221,760,000.00 $
2010 12 -104,468,000.00 $
2009 12 -67,830,000.00 $
2008 12 -82,710,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 6,144,078,000.00 $
2016 12 4,449,245,000.00 $
2015 12 3,654,837,000.00 $
2014 12 2,542,325,000.00 $
2013 12 1,952,076,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 115,954,000
2016 12 116,367,000
2015 12 115,230,000
2014 12 113,413,000
2013 12 111,290,000

 












Bloomberg News for REGENERON PHARMACEUTICALS:



Google News for REGENERON PHARMACEUTICALS:

Fairfield Current - 12 hours ago
Parsec Financial Management Inc. Invests $892000 in Regeneron ...
Parsec Financial Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the fourth quarter, ...
PRNewswire (press release)
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2018 Earnings Conference Call February 6, 2019 8:30 AM ET. Company Participants.
PressOracle
Regeneron: Cheap Enough To Look Past The Eylea Valley
REGN's major 2017 product intro, Dupixent, is seeing booming sales. Dupixent probably has several new indications coming and is in the early ...
BharataPress
Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical ...
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Regeneron ...
Seeking Alpha - 6 Feb 2019
Regeneron Pharmaceuticals (REGN): Worth Watching Healthcare ...
Regeneron Pharmaceuticals (REGN):. Share of Regeneron Pharmaceuticals (REGN) stock price is settled at $414.97 after trading hours.
GuruFocus.com
Regeneron Pharmaceuticals beats by $1.23, beats on revenue
Regeneron Pharmaceuticals (NASDAQ:REGN): Q4 Non-GAAP EPS of $6.84 beats by $1.23; GAAP EPS of $7.15 beats by $1.73. Revenue of ...
Motley Fool
Analyst Commentary On Western Digital Corporation (WDC ...
As the normal trading session ended, the stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), fetched in a $2.88 spike to $414.97.
Benzinga
Sanofi and Regeneron to cut price of Praluent
Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi (NASDAQ:SNY) will adjust the U.S. list price of cholesterol ...
Seeking Alpha - 4 days ago
Analyst Research Roundup: San Juan Basin Royalty Trust (SJT ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is worth US$44.08 Billion and has recently risen 0.7% to US$414.97. The latest exchange ...
Zacks.com - 3 days ago
Regeneron Likely To Outperform In 2019
Regeneron (REGN) is a biotechnology company with a focus on helping patients with eye diseases, allergic & inflammatory conditions, cancer, ...


Back